A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT02212067
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
  • placebo — DRUG
    Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Study Details

This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.

Key Dates

Start date
Aug 11, 2014
Status verified
Mar 2018
Primary completion
May 11, 2015
Completion
May 11, 2015

Study Design

Enrollment
87 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Total of 12 visits
  • Placebo Comparator: Placebo
    Total of 12 visits
  • No Intervention: Healthy subjects
    Total of 2 visits

Primary Outcome Measure

Area under the serum insulin concentration time curve from 0 to 10 minutes after a 25 g glucose bolus i.v. infusion (IVGTT,intravenous glucose tolerance test) over 2 minutes [ Time Frame: Day -1, day 86 ]

Related Studies